Released Aug 8, 2016, after the close
10-Q filed Aug 8, 2016, 39 days after period end · 0001564590-16-023312
Q2 2016 · 10-Q
Revenue$1.03M$1.03M +212.2% vs Q2 2015−22.3% vs Q1 2016
Net Income-$8.41M-$8.41M N/M vs Q2 2015N/M vs Q1 2016
EPS Diluted-$0.29-$0.29 N/M vs Q2 2015N/M vs Q1 2016
Operating Income-$8,004,000N/M
Operating Cash Flowderived-$7,504,000N/M
Free Cash Flowderived-$7,710,000N/M
Margins · derived
Operating margin-779.4%+1414.6 pt vs Q2 2015
Net margin-818.7%+1545.7 pt vs Q2 2015
What the release said
No earnings release is on file for this quarter. Its figures came with the 10-Q.
Same quarter
| Metric | Q2 2016 | Q2 2015 | Q2 2014 | Q2 2013 |
|---|---|---|---|---|
| Revenue | $1.03M | $329.00K | — | $290.00K |
| Net Income | -$8.41M | -$7.78M | -$6.07M | -$5.53M |
| EPS Diluted | -$0.29 | -$0.33 | -$0.30 | -$4.46 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Fate Therapeutics Inc · CIK 1434316 · Engraved from SEC EDGAR